

Edgar Filing: GENOMED INC - Form NT 10-K

GENOMED INC  
Form NT 10-K  
March 28, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

COMMISSION FILE NUMBER 000-49720  
CUSIP 37243C 10 2

(Check One):  Form 10-KSB  Form 11-K  Form 10-QSB  Form N-SAR  
For Period Ended: DECEMBER 31, 2002

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Read attached instruction sheet before preparing form. Please print or type.  
Nothing in this form shall be construed to imply that the Commission has  
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify  
the item(s) to which the notification relates: \_\_\_\_\_

PART I -- REGISTRANT INFORMATION

Full name of registrant GenoMed, Inc.

Former name if applicable

Address of principal executive office (Street and number): 4560 Clayton Avenue

City, state and zip code St. Louis, Missouri 63110

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense  
and the registrant seeks relief pursuant to Rule 12b-25(b), (Paragraph 23, 047),  
the following should be completed. (Check box if appropriate.)

- | (a) The reasons described in reasonable detail in Part III of this form  
could not be eliminated without unreasonable effort or expense;
- | (b) The subject annual report, semi-annual report, transition report on  
Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or  
before the 15th calendar day following the prescribed due date; or the subject  
quarterly report or transition report on Form 10-Q, or portion thereof will be  
filed on or before the fifth calendar day following the prescribed due date; and  
(Amended in Release No. 34-26589 (Paragraph 72, 435), effective April 12, 1989,  
54 F.R. 10306.)
- | (c) The accountant's statement or other exhibit required by Rule 12b-25(c)  
has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR or

Edgar Filing: GENOMED INC - Form NT 10-K

the transition report portion thereof could not be filed within the prescribed time period. (Amended in Release No. 34-26589 (Paragraph 72, 435), effective April 12, 1989, 54 F.R. 10306.)

The Form 10-KSB could not be filed within the prescribed time because the Registrant requires additional time in order to finalize year-end financial information, complete consolidation of financial statements and complete managements discussion and analysis.

PART IV -- OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

<u>Brenda Hamilton, Esquire</u>	<u>561</u>	<u>416-8956</u>
(Name)	(Area Code)	(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  Yes  No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

GenoMed, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 27, 2003

/s/ Dr. David Moskowitz

PRESIDENT/CHIEF EXECUTIVE OFFICER/CHAIRMAN OF THE BOARD/CHIEF FINANCIAL OFFICER/CHIEF ACCOUNTING OFFICER